25.00p+0.00 (+0.00%)20 May 2022, 16:29
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Valirx PLC Fundamentals

Company NameValirx PLCLast Updated2022-05-20
IndustryBiotechnologySectorHealthcare
Shares in Issue65.049 mMarket Cap£16.26 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.04EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0162Debt Equity Ratio0.0119
Asset Equity Ratio1.0317Cash Equity Ratio0.3077
Quick Ratio16.2940Current Ratio16.74
Price To Book Value3.8820ROCE0

Valirx PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Valirx PLC Company Financials

Assets20202019
Tangible Assets£20,995.000
Intangible Assets£2.93 m£3.22 m
Investments00
Total Fixed Assets£2.95 m£3.22 m
Stocks00
Debtors£54,156.00£45,243.00
Cash & Equivalents£1.85 m0
Other Assets00
Total Assets£4.94 m£3.60 m
Liabilities20202019
Creditors within 1 year£124,478.00£1.38 m
Creditors after 1 year£57,925.000
Other Liabilities00
Total Liabilities£182,403.00£1.38 m
Net assets£4.76 m£2.22 m
Equity20202019
Called up share capital£9.67 m£9.42 m
Share Premium£24.38 m£20.60 m
Profit / Loss-£1.54 m-£2.72 m
Other Equity£4.91 m£2.35 m
Preference & Minorities-£155,888.00-£130,813.00
Total Capital Employed£4.76 m£2.22 m
Ratios20202019
Debt Ratio£0.010
Debt-to-Equity£0.010
Assets / Equity1.03171.0317
Cash / Equity0.30770.3077
EPS-£0.04-£0.33
Cash Flow20202019
Cash from operating activities-£1.91 m-£1.34 m
Cashflow before financing£1.94 m-£128,247.00
Increase in Cash£1.85 m-£378,506.00
Income20202019
Turnover00
Cost of sales00
Gross Profit00
Operating Profit-£1.65 m-£2.70 m
Pre-Tax profit-£1.54 m-£2.72 m

Valirx PLC Company Background

SectorHealthcare
ActivitiesValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers,specializing in the epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.
Latest Interim Date7 Sep 2021
Latest Fiscal Year End Date25 May 2022

Valirx PLC Directors

AppointedNamePosition
2013-10-08Mr. James Nicholas ThornileyNon-Executive Director,Chairman
2020-04-14Dr. George MorrisExecutive Director,Chief Operating Officer
2020-04-14Dr. Satu VainikkaExecutive Director,Chief Executive Officer
2021-04-30Mr. Gerald DeslerExecutive Director,Finance Director
2021-04-30Mr. Kevin J AlexanderNon-Executive Director,Company Secretary
2010-04-01Dr. Jacob MicallefExecutive Director,Chief Technical Officer
2007-10-25Mr. Anthony Roger MooreNon-Executive Director,Chairman
2020-07-03Mr. Oliver de Giorgio-MillerNon-Executive Director,Chairman
2019-05-31Mr. Seppo Olavi MakinenNon-Executive Director
2021-02-18Mr. Martin Lampshire Non-Executive Director
2021-02-18Dr. Suzanne Dilly Executive Director,Chief Executive Officer
2021-02-18Dr. Kevin Paul Cox Non-Executive Director,Chairman

Valirx PLC Contact Details

Company NameValiRx PLC
Address16 Upper Woburn Place, London, WC1H 0BS
Telephone+44 2030084416
Websitehttp://www.valirx.com

Valirx PLC Advisors

StockbrokerBeaufort Securities Ltd
Phone+44 2073828300
Fax+44 2073828400
SolicitorPinsent Masons LLP
Phone+44 2074187000
Fax+44 2074187050
AuditorAdler Shine LLP
Phone+44 2083713000
Fax+44 2083713099
BankRoyal Bank of Scotland PLC
Financial PR AdviserPeckwater PR
RegistrarCapita Asset Services
Phone+44 8704027573
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880